Sedana Medical AB (SEDANA) AI Stock Analysis

• Market Cap: €1.23B
• Dividend Yield: N/A
• Average Volume (3M): 368.74K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 13.66%
• EPS Growth: -139.90%
• Country: SE
• Employees: 109
• Sector: Healthcare
• Sector Strength: 54
• Industry: Medical - Devices
• EPS (TTM): -0.24
• Shares Outstanding: 99,336,960
• 10 Day Avg. Volume: 393,144
• 30 Day Avg. Volume: 368,738
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Sedana Medical AB's stock is primarily influenced by its robust revenue growth and strong balance sheet. However, significant operational challenges, including negative profitability and cash flow issues, weigh heavily on its overall performance. The technical analysis points to a bearish trend, and the unattractive valuation due to a negative P/E ratio adds further pressure. While the company's financial stability is evident, the need for improved operational efficiency and profitability is critical for enhancing stock performance.

Sedana Medical AB Business Overview & Revenue Model

Company Description

Sedana Medical AB (SEDANA) is a Swedish medical technology company that specializes in developing, marketing, and selling medical devices and pharmaceuticals for inhalation sedation. Sedana Medical's core product is the AnaConDa, a system designed to administer volatile anesthetics for sedation in intensive care units. The company operates primarily within the healthcare sector, focusing on providing innovative solutions to improve patient care and outcomes in critical care settings.

How the Company Makes Money

Sedana Medical makes money primarily through the sales of its AnaConDa system and related consumables. The AnaConDa system is sold to hospitals and healthcare facilities, where it is used for sedating patients in intensive care units. Revenue is generated from both the initial sale of the AnaConDa device and the recurring sales of consumables required for its operation. Sedana Medical may also generate revenue through partnerships and collaborations with healthcare providers and distributors, as well as through potential licensing agreements for its technology.

Sedana Medical AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
178.75M	153.87M	122.86M	159.15M	141.77M
	Gross Profit
126.14M	108.98M	86.07M	106.71M	88.90M
	EBIT
-50.77M	-65.55M	-103.93M	-61.20M	-21.54M
	EBITDA
-29.17M	-51.67M	-64.87M	-49.10M	-17.22M
	Net Income Common Stockholders
-10.67M	-59.61M	-73.51M	-57.97M	-27.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
193.96M	381.80M	607.74M	836.18M	376.17M
	Total Assets
1.02B	1.01B	1.08B	1.17B	600.10M
	Total Debt
5.92M	4.31M	8.74M	8.87M	8.29M
	Net Debt
-188.04M	-226.87M	-599.00M	-827.31M	-367.88M
	Total Liabilities
61.17M	44.06M	52.43M	66.12M	49.00M
	Stockholders Equity
958.26M	970.00M	1.03B	1.10B	551.09M
Cash Flow		Free Cash Flow
-186.77M	-206.95M	-253.22M	-151.48M	-92.47M
	Operating Cash Flow
-11.77M	-38.06M	-115.43M	-41.22M	-7.85M
	Investing Cash Flow
-44.67M	-321.96M	-137.78M	-110.25M	-84.62M
	Financing Cash Flow
-3.57M	-4.86M	-1.51M	605.07M	5.79M

Sedana Medical AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.28
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SEDANA, the sentiment is Neutral. The current price of 13.28 is above the 20-day moving average (MA) of 9.73, above the 50-day MA of 11.68, and below the 200-day MA of 17.03, indicating a neutral trend. The MACD of 0.44 indicates Negative momentum. The RSI at 69.16 is Neutral, neither overbought nor oversold. The STOCH value of 83.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SEDANA.

Sedana Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	74 Outperform	€1.06B	18.74	18.74%	―	10.46%	22.82%
MNTC	54 Neutral	kr524.16M	―	-12.29%	―	6.11%	-553.72%
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
ACARIX	46 Neutral	kr207.86M	―	-102.63%	―	-0.61%	54.19%
SEDANA	46 Neutral	€1.23B	―	-5.61%	―	13.66%	-139.90%
BACTI.B	46 Neutral	€1.05B	―	-7.30%	―	23.51%	80.47%
INTEG.B	43 Neutral	€317.03M	―	-12.79%	―	-6.43%	-323.52%

Sedana Medical AB Corporate Events

Sedana Medical Reports Record Quarter with Strong Sales Growth

Sedana Medical AB reported a record quarter with net sales increasing by 18% compared to the same period in 2024, driven by its focus on inhaled sedation products. Despite facing negative currency effects, the company showed improved financial performance with a reduced EBITDA loss and positive cash flow from operating activities, highlighting its strong market positioning and operational resilience.